Inotek Pharmaceuticals Corp. Company Profile (NASDAQ:ITEK)

Analyst Ratings

Consensus Ratings for Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.00 (197.13% upside)

Analysts' Ratings History for Inotek Pharmaceuticals Corp. (NASDAQ:ITEK)
Show:
DateFirmActionRatingPrice TargetActions
7/20/2016Piper Jaffray Cos.Set Price TargetBuy$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015NomuraReiterated RatingBuy$13.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015Cowen and CompanyReiterated RatingOutperform$15.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Inotek Pharmaceuticals Corp. (NASDAQ:ITEK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/11/2016Q1($0.22)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2016Q4($0.37)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2015Q115($0.40)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Inotek Pharmaceuticals Corp. (NASDAQ:ITEK)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Inotek Pharmaceuticals Corp. (NASDAQ:ITEK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Inotek Pharmaceuticals Corp. (NASDAQ:ITEK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/13/2016J Martin CarrollDirectorBuy10,000$9.03$90,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015Argeris N KarabelasDirectorBuy603,832$6.00$3,622,992.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015Park Bioventures Lp DevonMajor ShareholderBuy814,166$6.00$4,884,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Inotek Pharmaceuticals Corp. (NASDAQ:ITEK)
DateHeadline
07/27/16 07:31 AMInotek Pharmaceuticals Corporation (ITEK) Updated Price Targets - FTSE News
07/23/16 08:43 AMIs $40 Price Target Attainable For Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)? - Investor Newswire
07/22/16 04:38 PMInotek Pharmaceuticals Corporation (NASDAQ:ITEK): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/22/16 07:18 AMInotek Pharmaceuticals Expands Intellectual Property Portfolio with Combination Patent - [at noodls] - - Covers Combination of Trabodenosonand a Prostaglandinfor Reducing Intraocular Pressure in Glaucoma - LEXINGTON, Mass.--(BUSINESS WIRE)--Jul. 22, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), ...
07/21/16 10:45 AMInotek Pharmaceuticals Corporation (NASDAQ:ITEK) Shorted Shares Increased By 110.52% - Consumer Eagle
07/20/16 07:43 AMActive Stocks to Watch: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), REEDS, Inc. (NYSEMKT:REED), WGL ... - KC Register
07/20/16 07:43 AMEquity Roundup: Stock Performance Focus on Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - Press Telegraph
07/19/16 10:49 AMInotek Pharmaceuticals Corporation (NASDAQ:ITEK) increased 3.12%: Tesaro, Inc. (NASDAQ:TSRO), Yahoo! Inc ... - KC Register
07/18/16 04:53 PMHere's Why We Are Avoiding Inotek Pharmaceuticals
07/18/16 09:58 AMShares Moving Down on the Week: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - Engelwood Daily
07/16/16 08:06 AMShares Experiencing a Downtrend: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - TGP
07/16/16 08:06 AMStrong Sell Calls For Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) At 0 - Investor Newswire
07/15/16 03:47 PMIncreased Volatility Noted on Shares of: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - Engelwood Daily
07/15/16 03:47 PMInotek Pharmaceuticals Corporation (NASDAQ:ITEK) Short Interest Decreased By 24.03% - Consumer Eagle
07/15/16 08:25 AMInotek Pharmaceuticals Corporation (NASDAQ:ITEK) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 08:25 AMInotek Pharmaceuticals Corporation Realized Volatility Hits Extreme Level - CML News
07/14/16 04:52 PMAnalyst Target and Average Rating Watch: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - Press Telegraph
07/14/16 04:52 PMInotek Pharmaceuticals Corporation (ITEK) Current Analyst Ratings - Fiscal Standard
07/14/16 07:12 AMINOTEK PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/13/16 05:05 PMInotek Pharma (ITEK) Begins Phase 2 Dose-ranging Trial of FDC of Trabodenoson
07/12/16 04:57 PMInotek Pharma (ITEK) Begins Phase 2 Dose-ranging Trial of FDC of Trabodenoson - StreetInsider.com
07/12/16 04:57 PMInotek Pharmaceuticals Corporation (NASDAQ:ITEK) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/12/16 03:33 PMInotek Pharmaceuticals Initiates Phase 2 Dose-ranging Trial of a Fixed-Dose Combination of Trabodenoson, a Novel Treatment for Glaucoma, and Latanoprost - [at noodls] - -Data Expected in 2017- LEXINGTON, Mass--(BUSINESS WIRE)--Jul. 12, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development ...
07/12/16 03:17 PM4:17 pm Inotek Pharmaceuticals announces the initiation of a phase 2 dose-ranging trial of a fixed-dose combination of trabodenoson & latanoprost, data expected in 2017 -
07/08/16 04:52 PMIs $40 Within Reach For Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)? - Investor Newswire
07/08/16 06:21 AMInotek Pharmaceuticals to Present at Upcoming Investor Conferences - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)--Jul. 8, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization ...
07/07/16 04:46 PMInotek Pharmaceuticals Corporation Stock Momentum Hits Extreme Weakness - CML News
07/07/16 04:46 PMHeightened Volatility Check on: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - Engelwood Daily
07/07/16 07:37 AMCompany Stock Focus for Inotek Pharmaceuticals Corporation (NASDAQ:ITEK): Which Way Will Shares Head? - Press Telegraph
07/01/16 04:42 PMInotek Pharmaceuticals Corporation (NASDAQ:ITEK) Expected to Reach Highs Of $40 - Investor Newswire
06/30/16 07:36 AMWhy Making Dramatic Moves: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), Navidea Biopharmaceuticals ... - KC Register
06/30/16 07:36 AMWatching Stock Volatility for: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - Engelwood Daily
06/30/16 07:36 AMCovering the Bases on Inotek Pharmaceuticals Corporation (NASDAQ:ITEK): Where is the Stock Going? - Press Telegraph
06/29/16 07:31 AMCheck on Share Volatility: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - Engelwood Daily
06/27/16 04:27 PMINOTEK PHARMACEUTICALS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/26/16 04:04 PMInotek Pharmaceuticals Corporation (NASDAQ:ITEK) Went Up 3.26%: Republic Services, Inc. (NYSE:RSG), General ... - KC Register
06/26/16 04:04 PMShare Volatility Check for: Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) - Press Telegraph
06/24/16 07:20 AMInotek Pharmaceuticals Corporation (NASDAQ:ITEK) Earnings Glance and Target Price Review - Engelwood Daily
06/22/16 09:23 AMInotek Pharmaceuticals Corporation (NASDAQ:ITEK) plummeted -6.32%: Maiden Holdings, Ltd. (NASDAQ:MHLD ... - KC Register
06/18/16 09:04 AMStrong Buy Calls Count For Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) At 2 - Investor Newswire
06/16/16 07:39 AMInotek Pharmaceuticals Announces Participation in Fireside Chat at JMP Securities 2016 Life Sciences Conference - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 16, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization ...
06/15/16 03:23 PMBeleaguered Valeant Appoints Lead Independent Director -
06/13/16 04:26 PMTrending Stocks: Vail Resorts (NYSE:MTN), Inotek Pharmaceuticals (NASDAQ:ITEK), Aratana (NASDAQ:PETX), Taro ... - KC Register
06/06/16 01:26 PMInotek Pharmaceuticals Corp. :ITEK-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
06/05/16 07:25 AMCan Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Meet Analysts Expectations? - Stocks Daily
06/02/16 04:58 PMInotek Pharmaceuticals Corporation (ITEK) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Inotek Pharmaceuticals Corporation (ITEK) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Inotek Pharmaceuticals Corporation (ITEK). The latest reports which are currently in issue on Thursday 2nd of June state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/26/16 12:24 PMNew Broker Ratings For Inotek Pharmaceuticals Corporation (ITEK) - FTSE News - New Broker Ratings For Inotek Pharmaceuticals Corporation (ITEK)FTSE News07/23/2015 – Inotek Pharmaceuticals Corporation had its “buy” rating reiterated by analysts at Nomura. They now have a USD 30 price target on the stock. The share price of Inotek Pharmaceuticals Corporation (ITEK) was down -2.26% during the last ...
05/11/16 06:22 AMInotek Pharmaceuticals Corporation Reports First Quarter 2016 Financial Results and Operational Highlights - [at noodls] - Inotek Pharmaceuticals Corporation Reports First Quarter 2016 Financial Results and Operational Highlights
05/11/16 06:07 AMInotek Pharmaceuticals reports 1Q loss -
04/26/16 06:26 AMInotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 26, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization ...

Social

About Inotek Pharmaceuticals Corp.

Inotek Pharmaceuticals Corp. logoInotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye's natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye's trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ITEK
  • CUSIP:
Key Metrics:
  • Previous Close: $9.76
  • 50 Day Moving Average: $8.09
  • 200 Day Moving Average: $8.12
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $257.89M
  • Beta: 4.05
  • Current Year EPS Consensus Estimate: $-1.62 EPS
  • Next Year EPS Consensus Estimate: $-2.08 EPS
Additional Links:
Inotek Pharmaceuticals Corp. (NASDAQ:ITEK) Chart for Wednesday, July, 27, 2016